TenoMiR for Tendinopathy

---

Tendinopathy is estimated to affect 1 in 10 people during their lifetimes (1.4 million cases/year EU/US)[1]. Currently, the best treatment, physiotherapy only benefits 50% of cases. To treat tendinopathy, we have developed TenoMiR (CWT-001) a microRNA replacement therapy which directly targets critical disease pathways restoring tendons to normal structure and function. We have shown that a single local injection of TenoMiR improves tendon healing in mouse and equine tendinopathy models[2],[3]. Significantly, the pathophysiology of tendinopathy is conserved at the molecular level in mice, horses, and humans, giving us confidence that findings from animal models will translate into humans.  TenoMiR is unique in that it directly targets the key changes in collagen production associated with tendinopathy. Unlike other therapies, TenoMiR has a well-defined mode-of-action that is supported by a wealth of scientific data. Moreover, treatment with TenoMiR does not require invasive biopsies and can be delivered at the point of initial diagnosis initiating recovery at the very earliest time.  We believe based on our proof-of-concept data in mice and horses, that treatment with TenoMiR will tendon improve tendon healing, reducing both pain and recovery time.
[1] Walker Bone et al., 2012 Rhematology
[2] Millar et al., 2015 Nature Communications
[3] Watts et al., 2017 Cell Molecular Therapy